相似文献
1
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12.
2
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.
3
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Haematologica. 2007 May;92(5):612-8. doi: 10.3324/haematol.10965.
4
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
Cancer. 2016 Jul 15;122(14):2178-85. doi: 10.1002/cncr.30031. Epub 2016 May 3.
5
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.
6
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.
7
Durable remissions in positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation.
Haematologica. 2019 Jun;104(6):e244-e247. doi: 10.3324/haematol.2018.210104. Epub 2019 Feb 14.
8
Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.
Bone Marrow Transplant. 2016 Sep;51(9):1253-5. doi: 10.1038/bmt.2016.104. Epub 2016 Apr 18.
9
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
10
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Haematologica. 2015 Jul;100(7):e261-4. doi: 10.3324/haematol.2014.117424. Epub 2015 Mar 13.
引用本文的文献
1
Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia.
Cancers (Basel). 2025 Feb 25;17(5):779. doi: 10.3390/cancers17050779.
2
GNA15 induces drug resistance in B cell acute lymphoblastic leukemia by promoting fatty acid oxidation via activation of the AMPK pathway.
Mol Cell Biochem. 2025 Jun;480(6):3719-3733. doi: 10.1007/s11010-024-05198-4. Epub 2025 Jan 15.
3
Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.
Cancer Med. 2024 Dec;13(24):e70515. doi: 10.1002/cam4.70515.
4
Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia.
Haematologica. 2024 Jun 1;109(6):1668-1676. doi: 10.3324/haematol.2023.283818.
5
All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia.
Hematol Transfus Cell Ther. 2024 Apr-Jun;46(2):192-200. doi: 10.1016/j.htct.2023.06.006. Epub 2023 Jul 31.
6
Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia.
Front Immunol. 2023 Jun 8;14:1191912. doi: 10.3389/fimmu.2023.1191912. eCollection 2023.
7
PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.
Sci Adv. 2022 Dec 14;8(50):eadd6403. doi: 10.1126/sciadv.add6403.
8
Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?
Clin Hematol Int. 2022 May 11;4(1-2):11-20. doi: 10.1007/s44228-022-00006-6. eCollection 2022 Jun.
9
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
Ther Adv Hematol. 2022 Jun 28;13:20406207221103321. doi: 10.1177/20406207221103321. eCollection 2022.
10
Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Cancer Treat Res. 2022;183:287-315. doi: 10.1007/978-3-030-96376-7_11.
本文引用的文献
1
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.
2
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
3
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10.
4
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.
Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64.
5
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.
Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.
6
Blinatumomab: a historical perspective.
Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24.
7
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.
8
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.
Blood. 2012 Aug 30;120(9):1868-76. doi: 10.1182/blood-2011-09-377713. Epub 2012 Mar 22.
9
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
Zotero 插件